LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC announces a class action lawsuit has been filed against Osiris Therapeutics, Inc. (“Osiris” or the “Company”) (Nasdaq: OSIR) concerning possible violations of federal securities laws between May 12, 2014 and November 20, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the January 22, 2016, lead plaintiff motion deadline.
To participate in this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at firstname.lastname@example.org.
According to the complaint, the Company announced that it has determined to correct the revenue recognition for three contracts which will result in a decrease in product revenues of $1.8 million in the first quarter of 2015, a decrease in product revenues of $1.0 million in the second quarter, an increase in product revenues of $0.8 million in the third quarter of 2015 and a decrease in product revenues of $1.1 million in 2014. When the truth was revealed, shares dropped causing investors harm.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.